Opendata, web and dolomites

OXYPREM SIGNED

Precise brain oxygen monitoring for high-risk preterm infants

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXYPREM project word cloud

Explore the words cloud of the OXYPREM project. It provides you a very rough idea of what is the project "OXYPREM" about.

fixed    commercialization    paralysis    biocompatible    meant    supply    zurich    irreversible    15    neonatologists    consists    savings    university    head    urgent    globally    transforming    cagr2017    opportunity    62    market    competitors    spin    algorithms    babies    oxygenation    born    annually    deaths    opposed    ones    reliability    sensor    o2    lacking    spectroscopy    off    precision    decrease    oximeter    neonatal    clinical    billion    brain    signals    tissue    variation    preterm    surviving    ag    oxyprem    respiratory    unmet    oxygen    therapy    translates    compelling    variations    grow    2024    initially    world    preterms    running    disabilities    capitalizing    adults    medical    impairment    unnecessary    company    neurodevelopment    reusable    intensive    nirs    million    levels    oximeters    5x    disposable    damage    care    chronic    silicone    infrared    immature    life    actual    created    designed    global    monitor    shown    easier    reducing    prototypes    little    quality    saturation    435    answer    business    degree    die    alerting    cardiovascular    viability    worth    swiss    near   

Project "OXYPREM" data sheet

The following table provides information about the project.

Coordinator
OXYPREM AG 

Organization address
address: FRAUENKLINIKSTRASSE 10
city: ZURICH
postcode: 8091
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXYPREM AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Globally, 15 million preterm babies are born annually (435,000 in Europe), from which 1 million die. Even when surviving, they may face disabilities, such as neurodevelopment impairment or paralysis. Since their respiratory and cardiovascular systems are immature, they need early oxygen (O2) therapy. Tissue oximeters are medical devices needed to monitor the actual level of O2 supply in their brain, since little O2 variations can produce irreversible damage. However, current devices are adapted from tissue oximeters initially meant for adults, lacking the precision and reliability preterm babies need. World leading neonatologists have been alerting about the urgent need to develop tissue oximeters specifically designed for preterms, to decrease unnecessary deaths and chronic disabilities. OxyPrem is our answer: a brain oximeter created just for preterm babies and providing the degree of precision and reliability they need. OxyPrem consists of (1) a high-quality Near-Infrared Spectroscopy (NIRS) sensor embedded in biocompatible silicone that is fixed to the preterm's head to monitor brain O2-levels, and a (2) monitor running advanced analysis algorithms transforming the signals into tissue oxygenation saturation measurements. OxyPrem prototypes have shown unmet levels of precision in clinical studies, reducing 5x the variation observed with competitors. Furthermore, our reusable sensor (opposed to the disposable ones from competitors), translates into important savings. OxyPrem represents a compelling business opportunity, capitalizing from the global neonatal intensive care market, worth €5.6 billion and expected to grow at a CAGR2017-2024 of 5.62%. The commercialization of OxyPrem is key to the viability of our company OxyPrem AG, a Swiss spin-off from University of Zurich, born to make preterm life's easier.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXYPREM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXYPREM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More